Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAtapattu, Lakmali-
dc.contributor.authorSaha, Nayanendu-
dc.contributor.authorChheang, Chanly-
dc.contributor.authorEissman, Moritz F-
dc.contributor.authorXu, Kai-
dc.contributor.authorVail, Mary E-
dc.contributor.authorHii, Linda-
dc.contributor.authorLlerena, Carmen-
dc.contributor.authorLiu, Zhanqi-
dc.contributor.authorHorvay, Katja-
dc.contributor.authorAbud, Helen E-
dc.contributor.authorKusebauch, Ulrike-
dc.contributor.authorMoritz, Robert L-
dc.contributor.authorDing, Bi-Sen-
dc.contributor.authorCao, Zhongwei-
dc.contributor.authorRafii, Shahin-
dc.contributor.authorErnst, Matthias-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorNikolov, Dimitar B-
dc.contributor.authorLackmann, Martin-
dc.contributor.authorJanes, Peter W-
dc.identifier.citationJournal of Experimental Medicine 2016; 213(9): 1741-1757en_US
dc.description.abstractThe transmembrane metalloprotease ADAM10 sheds a range of cell surface proteins, including ligands and receptors of the Notch, Eph, and erbB families, thereby activating signaling pathways critical for tumor initiation and maintenance. ADAM10 is thus a promising therapeutic target. Although widely expressed, its activity is normally tightly regulated. We now report prevalence of an active form of ADAM10 in tumors compared with normal tissues, in mouse models and humans, identified by our conformation-specific antibody mAb 8C7. Structure/function experiments indicate mAb 8C7 binds an active conformation dependent on disulfide isomerization and oxidative conditions, common in tumors. Moreover, this active ADAM10 form marks cancer stem-like cells with active Notch signaling, known to mediate chemoresistance. Importantly, specific targeting of active ADAM10 with 8C7 inhibits Notch activity and tumor growth in mouse models, particularly regrowth after chemotherapy. Our results indicate targeted inhibition of active ADAM10 as a potential therapy for ADAM10-dependent tumor development and drug resistance.en_US
dc.subjectADAM10 Protein-
dc.subjectNeoplasms, Experimental-
dc.subjectNeoplastic Stem Cells-
dc.titleAn activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growthen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Experimental Medicineen_US
dc.description.affiliatesStructural Biology Program, Memorial Sloan-Kettering Cancer, New York, NY, USAen_US
dc.description.affiliatesCancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australiaen_US
dc.description.affiliatesTumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia.en_US
dc.description.affiliatesDepartment of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australiaen_US
dc.description.affiliatesInstitute for Systems Biology, Seattle, WA, USAen_US
dc.description.affiliatesDepartment of Genetic Medicine, Weill Cornell Medical College, New York, NY, USAen_US
dc.description.affiliatesCancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australiaen_US
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.